None
Quote | Autolus Therapeutics plc (NASDAQ:AUTL)
Last: | $4.08 |
---|---|
Change Percent: | 0.71% |
Open: | $4.18 |
Close: | $4.08 |
High: | $4.29 |
Low: | $3.96 |
Volume: | 3,872,781 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Autolus Therapeutics plc (NASDAQ:AUTL)
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Pha...
Message Board Posts | Autolus Therapeutics plc (NASDAQ:AUTL)
Subject | By | Source | When |
---|---|---|---|
Found an interesting article | jondoeuk | investorshub | 05/11/2023 6:32:42 PM |
$AUTL good read | jondoeuk | investorshub | 05/11/2023 10:18:44 AM |
great article | jondoeuk | investorshub | 05/11/2023 6:41:46 AM |
The now last up | jondoeuk | investorshub | 05/11/2023 4:44:23 AM |
MomentumIts now last up | jondoeuk | investorshub | 05/09/2023 11:12:12 AM |
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-g...
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Pha...
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights befo...